Snippet Search

Searching 12,405,263 documents.
Discover how a particular term or phrase is used in scientific literature

Showing 1 to 25 of 1767 matching articles

Results per page:

... Drugs that are most frequently used include  mitomycin 
Peritoneal Dissemination of Gastrointestinal Tumors
Peritoneal Dissemination of Gastrointestinal Tumors
Amini, Afshin; Masoumi-Moghaddam, Samar; Morris, David L.
C, cisplatin, 5-fluorouracil, oxaliplatin, ...
... from colorectal and appendiceal cancer.  Mitomycin 
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis
Speeten, Kurt; Stuart, O. Anthony; Chang, David; Mahteme, Haile; Sugarbaker, Paul H.
C is a drug often used in this clinical ...
... treated with hyperthermic intraperitoneal  mitomycin 
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C
Sugarbaker, Paul H.; Stuart, O. Anthony; Carmignani, C. Pablo
C chemotherapy after a complete ...
... approach using chemotherapeutic agent  mitomycin 
Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
Kim, Seog-Young; Lee, Dae-Hee; Song, Xinxin; Bartlett, David L.; Kwon, Yong Tae; Lee, Yong J.
C, biologic agent tumor necrosis ...
... intravesical regimen that includes both  mitomycin 
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
Hayne, Dickon; Stockler, Martin; McCombie, Steve P.; Chalasani, Venu; Long, Anne; Martin, Andrew; Sengupta, Shomik; Davis, Ian D.
and BCG. ...
... polysaccharide potentiated the effects of  mitomycin 
Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo
Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo
Xiang, Jianfeng; Xiang, Yanjie; Lin, Shengming; Xin, Dongwei; Liu, Xiaoyu; Weng, Lingling; Chen, Tao; Zhang, Minguang
both in vitro and in vivo. ...
... To measure the clearance intraperitoneal  mitomycin 
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics
Lima Vazquez, Vinicius; Stuart, O. Anthony; Mohamed, Faheez; Sugarbaker, Paul H.
C and doxorubicin in patients having ...
... radiotherapy with capecitabine and  mitomycin 
Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma
Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma
Stojanovic, Suzana; Popov, Ivan; Radosevic-Jelic, Ljiljana; Micev, Marjan; Borojevic, Nenad; Nikolic, Vladimir; Krivokapic, Zoran; Kecmanovic, Dragutin; Gavrilovic, Dusica; Kezic, Iva
C in patients with locally advanced rectal ...
... contained in the classical aminoquinones (  mitomycin 
DNA Damaging Drugs
DNA Damaging Drugs
Weber, Georg F.
C, porfiromycin, KW-2149, streptonigrin), ...
... cell functions. We report that bleomycin,  mitomycin 
A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents
A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents
Mabeta, Peace; Pepper, Michael S.
C and cytoskeletal-disrupting drugs ...
... chemoradiation with infusional 5-FU and  mitomycin 
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal
Oliveira, Suilane Coelho Ribeiro; Moniz, Camila Motta Venchiarutti; Riechelmann, Rachel; Alex, Alexandra Kichfy; Braghirolli, Maria Ignez; Bariani, Giovanni; Nahas, Caio; Hoff, Paulo Marcelo Gehm
is the standard treatment for localized ...
... of capecitabine alone or combined with  mitomycin 
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
Cereda, S.; Milella, M.; Cordio, S.; Leone, F.; Aprile, G.; Galiano, A.; Mosconi, S.; Vasile, E.; Santini, D.; Belli, C.; Auriemma, A.; Novarino, A.; Vaccaro, V.; Martines, C.; Marino, D.; Lutrino, S. E.; Palazzo, V.; Reinach, B.; Aldrighetti, L.; Reni, M.
C. ...
... the effect on intestinal wound healing of  mitomycin 
The optimal starting time of postoperative intraperitoneal mitomycin-C therapy with preserved intestinal wound healing
The optimal starting time of postoperative intraperitoneal mitomycin-C therapy with preserved intestinal wound healing
Uzunkoy, Ali; Bolukbas, Cengiz; Horoz, Mehmet; Bolukbas, Fusun F; Kocyigit, Abdurrahim
-C administered at different times ...
... protects hypoxic cells against  mitomycin 
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase
Schlager, John J.; Powis, Garth
C cytotoxicity by metabolizing ...
... of the combination of docetaxel and  mitomycin 
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
Feliu, J.; Martín, G.; Castro, J.; Sundlov, A.; Rodriguez-Jaráiz, A.; Casado, E.; Lomas, M.; Madroñal, C.; Galán, A.; Belda, C.; Gonzalez-Barón, M.
C as second-line chemotherapy in patients ...
... Summary The bioreductive alkylating agent  mitomycin 
Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia
Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia
Ludwig, Christian U.; Peng, Yei Mei; Beaudry, Jon N.; Salmon, Sydney E.
C ( ...
... setting with doxorubicin monotherapy or  mitomycin 
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per E
combined with 5-fluorouracil. ...
... (25 mg/m2) iv q mo NR EMP (560 mg) daily  mitomycin 
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
Winquist, Eric; Waldron, Tricia; Berry, Scott; Ernst, D Scott; Hotte, Sébastien; Lukka, Himu
C (10 mg/m2) iv q mo Anderström, 1995 [72] ...
... lines for LMBC). HAIC protocols included  mitomycin 
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters
Tewes, Mitra; Peis, Michael Wilhelm; Bogner, Simon; Theysohn, Jens M.; Reinboldt, Marcus Paul; Schuler, Martin; Welt, Anja
/5-FU (70%), ...
... (5-FU), cisplatin, carboplatin,  mitomycin 
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck
Budach, W; Hehr, T; Budach, V; Belka, C; Dietz, K
C) were analyzed according to the employed ...
... carcinoma cell line HCT116 exposed to  Mitomycin 
Label free high throughput screening for apoptosis inducing chemicals using time-lapse microscopy signal processing
Label free high throughput screening for apoptosis inducing chemicals using time-lapse microscopy signal processing
Aftab, Obaid; Nazir, Madiha; Fryknäs, Mårten; Hammerling, Ulf; Larsson, Rolf; Gustafsson, Mats G.
, an apoptosis inducing drug, was labeled ...
... 44]. The most commonly reported agents are  mitomycin 
Thrombotic Microangiopathy Syndromes
Thrombotic Microangiopathy Syndromes
Zakarija, Anaadriana
-C, quinine, cyclosporine and ticlopidine ...
... or more cords. For experiments involving  mitomycin 
Chloride intracellular channel 4 is involved in endothelial proliferation and morphogenesis in vitro
Chloride intracellular channel 4 is involved in endothelial proliferation and morphogenesis in vitro
Tung, Jennifer J.; Hobert, Oliver; Berryman, Mark; Kitajewski, Jan
C treatment, cells were exposed to ...
... mouse embryonic stem cells to  mitomycin 
Drug therapy for hereditary cancers
Drug therapy for hereditary cancers
Imyanitov, Evgeny N; Moiseyenko, Vladimir M
C in a clonogenic assay; reversed upon ...
... The use of  mitomycin 
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
Poplin, Elizabeth A.; LoRusso, Patricia; Lokich, Jacob J.; Gullo, John J.; Leming, Philip D.; Schulz, Joseph J.; Veach, Stephen R.; McCulloch, William; Baker, L.; Schein, Philip
for metastatic colorectal cancer has been ...